The vasculitis clinic nurse’s communication challenge
The vasculitis clinic nurse works at the intersection of several forces that make patient and family communication systematically difficult: the diseases are rare enough that most patients and families arrive with no prior conceptual framework for understanding them; the treatments are immunosuppressive drugs whose names—rituximab, mepolizumab, cyclophosphamide, azathioprine—carry an association with cancer treatment that requires active reframing; the urgency of intervention often precedes visible illness, creating a mismatch between the aggressiveness of the treatment and the way the patient currently feels; and the consequences of under-treatment are irreversible in ways that other medical errors often are not.
Giant cell arteritis is the clearest example of the urgency-before-confirmation problem. The disease can blind a patient in one eye in a matter of hours, and the treatment window to prevent that outcome requires starting high-dose steroids immediately when the clinical picture is consistent, before the temporal artery biopsy — the diagnostic gold standard — has returned a result. To a family watching a treatment protocol begin for a disease that has not yet been confirmed, this looks like an error. The explanation requires teaching not only what GCA does to the arteries and optic nerve, but also why the biopsy result does not actually gate the treatment decision in this particular disease.
ANCA-associated vasculitis presents the opposite communication problem: the patient may not look dramatically ill, but the kidney damage is accumulating at a pace that the clinical appearance cannot convey. A creatinine rising from 3 to 7 mg/dL over three weeks represents hundreds of thousands of destroyed nephrons that will not be replaced. The treatment—rituximab plus high-dose steroids—looks like the treatment of last resort to a family seeing a patient who is still ambulatory and alert. The explanation requires teaching why the kidney pathology is both invisible and irreversible, and why the window to intervene is measured in weeks, not months.
EGPA presents the temporal reframing problem: the patient has had severe asthma for years, the family has organized their understanding of the disease around the respiratory system, and the rheumatologist is now reframing the entire illness as a systemic autoimmune vasculitis with a potentially fatal cardiac complication. The asthma was never just asthma—it was the first chapter of a different story. The explanation requires teaching the triphasic natural history of EGPA and, critically, reorienting the family’s concern away from the lungs and toward the heart.
Three conversations from the vasculitis clinic:
Scenario 1: Catalina Reyes-Montoya — 72, retired seamstress from El Paso, Texas
Catalina Reyes-Montoya had sewn her own wedding dress at nineteen, had taught her three daughters to sew before they were ten, and had, until six weeks ago, been sewing altar cloths for her parish’s daily mass. She was now sitting in the vasculitis clinic with the worst headache of her life: a constant, deep aching that spread from both temples to the back of her head, present every waking hour for eleven days. She had also developed pain in her jaw when she ate anything that required sustained chewing—she had switched to soft foods three days ago. She had not lost weight but had no appetite. She felt exhausted in a way that sleep did not fix.
Her son Manuel, a civil engineer who had driven from Las Cruces to be with her, had waited in the examination room while the rheumatologist reviewed her labs: ESR 98 mm/hr, CRP 4.8 mg/dL, platelet count 530,000—all markedly elevated. The rheumatologist had come in with the vasculitis clinic nurse, Graciela Montiel-Reyes, and had explained that the clinical picture was highly consistent with giant cell arteritis, a form of large-vessel inflammation that was a medical urgency. She was going to begin intravenous methylprednisolone today. A temporal artery biopsy had been scheduled for the day after tomorrow.
Manuel had listened carefully and had a direct question. “Doctor, yo entiendo que es urgente, pero ¿por qué empiezan el tratamiento hoy si no tienen el diagnóstico confirmado? ¿No deberían esperar la biopsia para saber si de verdad es esta enfermedad antes de darle un medicamento tan fuerte?” (Doctor, I understand it’s urgent, but why are you starting treatment today if you don’t have a confirmed diagnosis? Shouldn’t you wait for the biopsy to know if it’s really this disease before giving such a strong medication?)
It was exactly the right question. Graciela invited Manuel and Catalina to sit and walked through the reasoning.
“La pregunta de Manuel es muy lógica,” she began. “En la mayoría de las enfermedades, primero se confirma el diagnóstico y después se empieza el tratamiento. La arteritis de células gigantes es una excepción, y hay una razón muy específica para eso.” (Manuel’s question is very logical. In most diseases, you confirm the diagnosis first and then start the treatment. Giant cell arteritis is an exception, and there is a very specific reason for that.)
She explained the anatomy. The giant cell arteritis, she said, inflames the walls of medium and large arteries, particularly those that branch from the main arteries supplying the head. Among those branches is the ophthalmic artery—the artery that carries blood to the optic nerve, the bundle of nerve fibers that transmits visual information from the retina to the brain. When the ophthalmic artery becomes inflamed and narrowed from GCA, it can occlude suddenly. When blood flow to the optic nerve is cut off, the optic nerve undergoes ischemic infarction: the nerve tissue dies from lack of oxygen.
“El nervio óptico es tejido del sistema nervioso central,” Graciela said, “igual que el cerebro. Y como el cerebro, el nervio óptico no se regenera. Si la arteria del ojo se tapa por la arteritis y el nervio muere, la vista de ese ojo se pierde para siempre. No temporalmente — para siempre.” (The optic nerve is central nervous system tissue, just like the brain. And like the brain, the optic nerve does not regenerate. If the eye’s artery is blocked by the arteritis and the nerve dies, the vision in that eye is lost forever. Not temporarily — forever.)
Manuel absorbed this. “¿Con qué frecuencia pasa eso?” (How often does that happen?)
“En pacientes con arteritis de células gigantes que no se tratan, aproximadamente uno de cada cinco puede perder vista en uno o en los dos ojos. No es raro. Y la parte crítica es la velocidad: no pasa en semanas. Puede pasar en horas o en días. Los síntomas que tiene su madre ahora mismo — el dolor de cabeza, el dolor al masticar — son la señal de que la inflamación está activa. La ventana para actuar es muy corta.” (In patients with giant cell arteritis who are not treated, approximately one in five can lose vision in one or both eyes. It is not rare. And the critical part is the speed: it does not happen over weeks. It can happen in hours or days. The symptoms your mother has right now — the headache, the pain when chewing — are the signal that the inflammation is active. The window to act is very short.)
Manuel looked at his mother, then back at Graciela. “Pero la biopsia va a confirmar el diagnóstico. ¿Por qué no esperamos dos días?” (But the biopsy will confirm the diagnosis. Why not wait two days?)
Graciela had answered this question many times, and she appreciated that Manuel was asking it clearly rather than simply complying without understanding. “Hay dos razones. La primera: si esperamos dos días y su madre tiene la arteritis activa, esos son dos días en los que la arteria del ojo puede taparse. No podemos devolver la vista perdida. La segunda razón es que el tratamiento con esteroides no cambia la biopsia en las primeras dos semanas — empieza hoy y la biopsia de pasado mañana va a dar el mismo resultado que daría hoy. Los esteroides no destruyen la evidencia histórica de inmediato. Entonces no perdemos diagnóstico por empezar el tratamiento.” (There are two reasons. First: if we wait two days and your mother has active arteritis, those are two days in which the artery to the eye can block. We cannot return lost vision. The second reason is that steroid treatment does not change the biopsy in the first two weeks — start today and the day-after-tomorrow biopsy will give the same result it would give today. Steroids do not destroy the histological evidence immediately. So we lose nothing diagnostically by starting treatment.)
“Y la biopsia — ¿siempre sale positiva si hay arteritis?” (And the biopsy — does it always come back positive if there is arteritis?)
“No siempre. La arteritis de células gigantes inflama la arteria en parches — hay segmentos inflamados y segmentos normales intercalados. Si la biopsia toma un segmento normal, puede salir negativa aunque la enfermedad esté activa. Por eso la biopsia no es el último juicio — el diagnóstico final combina el resultado de la biopsia con el cuadro clínico, los análisis de sangre, y la respuesta al tratamiento. Una biopsia negativa no descarta la arteritis si todo lo demás apunta a ella.” (Not always. Giant cell arteritis inflames the artery in patches — there are inflamed segments and normal segments interspersed. If the biopsy samples a normal segment, it can come back negative even when the disease is active. That is why the biopsy is not the final verdict — the final diagnosis combines the biopsy result with the clinical picture, the blood tests, and the response to treatment. A negative biopsy does not rule out the arteritis if everything else points to it.)
Catalina had been quiet through the conversation. She asked the question she had been holding: “¿Quiere decir que podría quedarme ciega si no me tratan hoy?” (Does this mean I could go blind if they don’t treat me today?)
“Sí, señora Catalina. Ese es el riesgo que queremos evitar. Los esteroides van a bajar la inflamación y proteger la arteria del ojo. No podemos garantizar que nada malo vaya a pasar, pero sí sabemos que los esteroides reducen el riesgo significativamente si se dan a tiempo. Y a tiempo significa hoy.” (Yes, Catalina. That is the risk we want to avoid. The steroids will lower the inflammation and protect the artery to the eye. We cannot guarantee nothing bad will happen, but we do know that steroids reduce the risk significantly if given in time. And in time means today.)
Manuel nodded. “Entonces el riesgo de esperar es la ceguera permanente, y el riesgo de empezar hoy es … no confirmar todavía el diagnóstico.” (So the risk of waiting is permanent blindness, and the risk of starting today is … not yet confirming the diagnosis.)
“Exactamente. Y los dos días de diferencia no cambian la biopsia. La decisión no es difícil cuando se ve así.” (Exactly. And the two-day difference does not change the biopsy. The decision is not hard when seen this way.)
Scenario 2: Hernán Guerrero-Castellanos — 54, auto mechanic from Houston, Texas
Hernán Guerrero-Castellanos had been changing transmissions and rebuilding engines for twenty-six years. He was methodical, careful with his hands, and in the vocabulary of his trade: when something was wrong with a machine, you found the part that failed, you fixed it, and you tested it. He had come to the vasculitis clinic because his primary care doctor had referred him after three months of blood test abnormalities that had not resolved.
The clinical picture was specific: he had developed intermittent sinusitis six months ago, followed by fatigue and mild ankle swelling. Blood work had shown rising creatinine: 1.8 mg/dL in June, 3.4 mg/dL in August, 6.7 mg/dL last week. Urinalysis showed hematuria with red cell casts. His MPO-ANCA had returned strongly positive at 187 AU/mL. A kidney biopsy had been performed four days ago; the result, which the vasculitis clinic nurse Carmen Delgado-Viana was reviewing with him and his daughter Sofía today, showed pauci-immune crescentic glomerulonephritis with 65 percent crescents.
Sofía was a certified public accountant. She was thirty-one, had driven in from Katy that morning, and had printed out the kidney biopsy report, the MPO-ANCA result, and a summary of ANCA-associated vasculitis she had found on two academic medical center websites. She had a list of questions. The first one came before Carmen had finished her introduction.
“Holí, doctora — enfermera — perdón. Papi no tiene dolor. No tiene fiebre. Está un poco cansado pero maneja el carro, va al trabajo, hace sus cosas. ¿Por qué el plan de tratamiento es rituximab más metilprednisolona intravenosa cuando él está funcionando? El rituximab es un medicamento de cáncer. Me parece demasiado agresivo para la situación actual.” (Hi, doctor — nurse — sorry. Dad doesn’t have pain. He doesn’t have fever. He’s a little tired but he drives, goes to work, does his things. Why is the treatment plan rituximab plus intravenous methylprednisolone when he is functioning? Rituximab is a cancer drug. It seems too aggressive for the current situation.)
Carmen recognized the framing immediately: the patient’s appearance was providing a false reference point. She took the kidney biopsy report, turned it to the microscopy image page, and placed it on the table between them.
“Sofía, tiene razón en que su papá no se ve críticamente enfermo. El problema es que lo que está pasando en sus riñones no se ve desde afuera. Vamos a ver exactamente qué está pasando ahí adentro.” (Sofía, you’re right that your dad doesn’t look critically ill. The problem is that what is happening in his kidneys is not visible from the outside. Let’s look at exactly what is happening inside.)
She explained the kidney’s filtration architecture. Each kidney, she said, contains approximately 700,000 to one million nephrons—individual filtration units. Each nephron contains a glomerulus: a tiny knot of capillaries enclosed in a double-walled cup called Bowman’s capsule. Blood under pressure is filtered through the glomerular capillary walls into Bowman’s space; the filtrate becomes urine; waste products and excess fluid are removed from the blood. In a healthy adult, this filtration process occurs 180 liters of blood per day.
“En la vasculitis por ANCA,” she continued, “el sistema inmune produce anticuerpos — los ANCA — que se pegan a las células de defensa del cuerpo llamadas neutrófilos y las activan dentro de las paredes de los vasos sanguíneos pequeños, incluyendo los capilares del glomérulo. Cuando esos neutrófilos se activan dentro de la pared del vaso, destruyen la pared desde adentro. Eso se llama necrosis fibrinoide — la pared del capilar se destruye.” (In ANCA vasculitis, the immune system produces antibodies — the ANCA — that attach to the body’s defense cells called neutrophils and activate them inside the walls of small blood vessels, including the capillaries of the glomerulus. When those neutrophils activate inside the vessel wall, they destroy the wall from the inside. That is called fibrinoid necrosis — the capillary wall is destroyed.)
She pointed to the biopsy image. “Cuando la pared del capilar glomerular se destruye, el cuerpo trata de repararla y manda células inflamatorias al espacio de Bowman — el espacio alrededor del glomérulo. Esas células forman lo que la biopsia llama una ‘media luna’ o ‘creciente’ — una media luna que aplasta el glomérulo desde afuera. Cuando el glomérulo está aplastado, deja de filtrar. La nefrona muere.” (When the glomerular capillary wall is destroyed, the body tries to repair it and sends inflammatory cells to Bowman’s space — the space around the glomerulus. Those cells form what the biopsy calls a ‘crescent’ — a crescent that crushes the glomerulus from the outside. When the glomerulus is crushed, it stops filtering. The nephron dies.)
Sofía was reading the biopsy report alongside the explanation. “‘65 por ciento de crecientes.’ ¿Eso qué significa?” (‘65 percent crescents.’ What does that mean?)
“Significa que en la muestra de riñón que tomaron, 65 de cada 100 nefronas tienen una media luna. Esas nefronas ya no están filtrando. Muchas de ellas ya no van a recuperarse.” (It means that in the kidney sample they took, 65 out of every 100 nephrons have a crescent. Those nephrons are no longer filtering. Many of them are not going to recover.)
Hernán had been listening with the focused attention he brought to complex mechanical problems. “Pero — los riñones están haciendo nuevas nefronas para reemplazar las que se pierden, ¿verdad?” (But — the kidneys are making new nephrons to replace the ones being lost, right?)
Carmen shook her head. “No, señor Hernán. Ese es el punto más importante. Los riñones de un adulto no hacen nefronas nuevas. Las que tenemos al nacer son las que tenemos para toda la vida. Cuando una nefrona muere — aplastada por una media luna fibrótica — esa pérdida es permanente. El riñón que queda distribuye el trabajo entre las nefronas que quedan, pero no repone las perdidas. Si perdemos suficientes nefronas, el riñón deja de poder filtrar suficiente para sobrevivir sin diálisis.” (No, Hernán. That is the most important point. An adult’s kidneys do not make new nephrons. The ones we have at birth are the ones we have for life. When a nephron dies — crushed by a fibrotic crescent — that loss is permanent. The remaining kidney distributes the work among the nephrons that remain, but it does not replace the ones lost. If we lose enough nephrons, the kidney can no longer filter enough to survive without dialysis.)
Sofía looked at the creatinine trend she had printed. “1.8 en junio, 3.4 en agosto, 6.7 la semana pasada. Eso es casi cuatro veces más alto en tres meses.” (1.8 in June, 3.4 in August, 6.7 last week. That is almost four times higher in three months.)
“Exactamente. Ese aumento de creatinina refleja la destrucción activa. Mientras la vasculitis está activa, las medias lunas siguen formándose y más nefronas se pierden cada semana. Si no detenemos la vasculitis ahora, la proyección es diálisis en semanas, no en meses.” (Exactly. That creatinine increase reflects active destruction. While the vasculitis is active, crescents keep forming and more nephrons are lost each week. If we do not stop the vasculitis now, the projection is dialysis in weeks, not months.)
Sofía had reached the treatment question on her list. “¿Por qué rituximab específicamente?” (Why rituximab specifically?)
“Los ANCA son anticuerpos. Los anticuerpos los producen células B y las células plasmáticas que vienen de células B. El rituximab se une a una proteína llamada CD20 que está en la superficie de las células B y las elimina — las vacía del cuerpo. Sin células B, no hay productores de ANCA nuevos. Los niveles de ANCA bajan. Los neutrófilos dejan de activarse en las paredes vasculares. La vasculitis se apaga.” (The ANCA are antibodies. Antibodies are produced by B cells and the plasma cells that come from B cells. Rituximab binds to a protein called CD20 that is on the surface of B cells and eliminates them — depletes them from the body. Without B cells, there are no new ANCA producers. ANCA levels fall. Neutrophils stop activating in vessel walls. The vasculitis switches off.)
“¿Y los esteroides?” (And the steroids?)
“El rituximab tarda unas semanas en eliminar todas las células B. Mientras actúa, los esteroides en altas dosis frenan la inflamación activa en el riñón — no eliminan la causa, pero apagan el fuego mientras el rituximab elimina el combustible.” (Rituximab takes a few weeks to eliminate all the B cells. While it acts, high-dose steroids stop the active inflammation in the kidney — they don’t eliminate the cause, but they put out the fire while rituximab eliminates the fuel.)
Hernán had been running the numbers in the way he ran diagnostics on engines: what is the known state, what is the failure mode, what is the repair window. “Entonces si no trato ahora, pierdo más filtros cada semana y los que pierdo no vuelven. Y si trato ahora, puedo parar la pérdida. Los filtros que ya se perdieron no vuelven, pero los que quedan se protegen.” (So if I don’t treat now, I lose more filters each week and the ones I lose don’t come back. And if I treat now, I can stop the loss. The filters already lost don’t come back, but the ones remaining are protected.)
“Exactamente, señor Hernán. No podemos recuperar las 65 de 100 nefronas que ya tienen medias lunas. Pero podemos proteger las 35 que todavía funcionan — y con un buen tratamiento, es posible mantenerse fuera de diálisis indefinidamente con función renal reducida. El tiempo importa mucho.” (Exactly, Hernán. We cannot recover the 65 out of 100 nephrons that already have crescents. But we can protect the 35 that are still functioning — and with good treatment, it is possible to stay off dialysis indefinitely with reduced kidney function. Time matters a great deal.)
Scenario 3: Alejandra Vargas-Salinas — 44, preschool teacher from San Antonio, Texas
Alejandra Vargas-Salinas had managed her severe asthma with the same resigned competence she brought to the more difficult students in her preschool: you learned the triggers, you prepared for flares, you kept the rescue inhaler in your bag and the oral prednisone in the cabinet. She had been hospitalized twice in three years. She had been on inhaled corticosteroids, a long-acting beta-agonist, and a leukotriene receptor antagonist for four years. When the asthma still wasn’t fully controlled, her pulmonologist had started monthly mepolizumab injections eighteen months ago, which had reduced her oral prednisone use significantly.
She had come to the vasculitis clinic not for the asthma but for something new and frightening: three weeks ago, she had woken up with a dropped right foot. She could not dorsiflex her ankle. She had no back pain, no prior leg symptoms. A neurologist had found peripheral eosinophilia of 3,800 cells per microliter on her last complete blood count and had referred her urgently. A skin biopsy of a small palpable purpuric lesion on her shin had shown eosinophilic infiltration of small vessel walls. Her ANCA was negative. The vasculitis clinic rheumatologist had diagnosed EGPA — eosinophilic granulomatosis with polyangiitis — and was recommending intensification of mepolizumab dosing plus cyclophosphamide given the active vasculitic manifestations.
Her husband Eduardo, a high school history teacher, had come with her. He had prepared for the appointment by reading everything he could find about EGPA, and he had a specific confusion that he articulated carefully.
“Entiendo que el diagnóstico es EGPA. Pero Alejandra ha tenido asma severa desde que la conozco — diez años. ¿Cómo es posible que el asma que lleva diez años tratando ahora sea una vasculitis sistémica? ¿El asma cambió de naturaleza, o siempre fue esto? Y si siempre fue esto, ¿por qué no se detectó antes?” (I understand the diagnosis is EGPA. But Alejandra has had severe asthma since I’ve known her — ten years. How is it possible that the asthma she has been treating for ten years is now a systemic vasculitis? Did the asthma change nature, or was it always this? And if it was always this, why wasn’t it detected before?)
The vasculitis clinic nurse Rosa Jiménez-Vega appreciated the precision of Eduardo’s question. It was the right question, and answering it required explaining EGPA’s natural history rather than simply its diagnosis.
“Eduardo, tiene razón en que la pregunta es importante. La respuesta es que el asma nunca fue ‘solo asma’ en el caso de Alejandra — pero durante años se comportó como asma y no podía distinguirse de asma alérgica grave sin la información que tenemos ahora. Le explico cómo progresa esta enfermedad.” (Eduardo, you’re right that the question is important. The answer is that the asthma was never ‘just asthma’ in Alejandra’s case — but for years it behaved like asthma and could not be distinguished from severe allergic asthma without the information we have now. Let me explain how this disease progresses.)
She described EGPA’s three-phase natural history. The first phase—the allergic herald phase—is adult-onset severe asthma, often steroid-dependent, that begins years to more than a decade before the systemic disease declares itself. It is clinically indistinguishable from severe allergic asthma in this phase. The immune abnormality driving it—eosinophilic airway inflammation driven by dysregulated Th2 immunity and excessive IL-5 production—is the same abnormality that will eventually produce systemic vasculitis, but during the first phase it is confined to the airways.
“Durante la fase heraláldica,” Rosa said, “que puede durar años o décadas, la enfermedad se presenta como asma grave y rinitis alér-gica. No hay forma clínica de distinguirla del asma común en esa etapa si no hay eosinofilia muy alta ni síntomas sistémicos. Por eso no se detectó antes — porque en esa etapa, se ve igual que asma.” (During the herald phase, which can last years or decades, the disease presents as severe asthma and allergic rhinitis. There is no clinical way to distinguish it from common asthma at that stage if there is no markedly elevated eosinophilia or systemic symptoms. That is why it was not detected before — because in that stage, it looks just like asthma.)
The second phase, she continued, is the eosinophilic phase: peripheral hypereosinophilia above 1,500 cells per microliter (and often much higher), and eosinophilic tissue infiltration in various organs. Eosinophilic pneumonia, eosinophilic gastroenteritis, and the early stage of eosinophilic myocarditis can occur in this phase.
“El conteo de 3,800 eosinófilos de Alejandra indica que está en la segunda fase de la enfermedad,” Rosa explained. “Los eosinófilos son células del sistema inmune que en condiciones normales ayudan a defendernos de parásitos y participan en respuestas alérgicas. Cuando el cuerpo produce demasiados, como en el EGPA, empiezan a infiltrar tejidos. Cuando entran a tejidos sólidos — pulmones, corazón, nervios — liberan proteínas tóxicas que dañan las células de esos tejidos.” (Alejandra’s count of 3,800 eosinophils indicates that she is in the second phase of the disease. Eosinophils are immune system cells that under normal conditions help defend us from parasites and participate in allergic responses. When the body produces too many, as in EGPA, they begin to infiltrate tissues. When they enter solid tissues — lungs, heart, nerves — they release toxic proteins that damage the cells of those tissues.)
Eduardo had come to the cardiac question on his own. “Vi en lo que leí que el EGPA puede afectar el corazón. ¿Eso ya está pasando?” (I saw in what I read that EGPA can affect the heart. Is that already happening?)
“Por eso hacemos el ecocardiograma esta semana,” Rosa said. “El corazón es el órgano que más nos preocupa en el EGPA — más que el pulmón. Cuando los eosinófilos infiltran el músculo del corazón, liberan unas proteínas — la proteína básica mayor y la proteína catiónica eosinofílica — que son directamente tóxicas para las células del músculo cardíaco. Eso se llama miocarditis eosinofílica. Puede causar insuficiencia cardíaca, arritmias graves, y es la causa más frecuente de muerte relacionada con el EGPA. La parte importante es que la miocarditis eosinofílica puede ocurrir sin que la persona sienta nada anormal en el corazón — por eso necesitamos hacer el eco aunque Alejandra no tenga síntomas cardíacos.” (That is why we are doing the echocardiogram this week. The heart is the organ we are most concerned about in EGPA — more than the lung. When eosinophils infiltrate the heart muscle, they release proteins — major basic protein and eosinophil cationic protein — that are directly toxic to heart muscle cells. That is called eosinophilic myocarditis. It can cause heart failure, serious arrhythmias, and it is the most frequent cause of death related to EGPA. The important part is that eosinophilic myocarditis can occur without the person feeling anything abnormal in the heart — that is why we need to do the echo even though Alejandra does not have cardiac symptoms.)
The third phase, Rosa explained, is the vasculitic phase: necrotizing granulomatous vasculitis of small and medium vessels. The foot drop that Alejandra had developed three weeks ago was the vasculitic phase announcing itself through the peripheral nervous system. Mononeuritis multiplex—nerve infarction from vasculitis of the vasa nervorum, the tiny arteries that supply peripheral nerves—produces exactly this pattern: sudden onset, focal, involving a specific nerve rather than a dermatomal pattern, in this case the right common peroneal nerve producing foot drop.
“La caída del pie no es un derrame,” Rosa said to Eduardo. “Es un infarto del nervio. La vasculitis bloqueó la pequeña arteria que alimentaba el nervio ciemón derecho — ese es el nervio que controla el movimiento del pie hacia arriba. Sin suministro de sangre, el nervio fue dañado. Eso es la señal de que la enfermedad ya pasó a la fase vascuítica sistémica.” (The foot drop is not a stroke. It is a nerve infarction. The vasculitis blocked the small artery feeding the right peroneal nerve — that is the nerve that controls upward foot movement. Without blood supply, the nerve was damaged. That is the signal that the disease has entered the systemic vasculitic phase.)
“¿Eso se va a recuperar?” (Is that going to recover?)
“Depende del grado de daño del nervio y de qué tan rápido controlamos la vasculitis. Con tratamiento agresivo ahora, algunos pacientes recuperan función parcial o total en el nervio con el tiempo. Sin tratamiento, el daño progresa a más nervios y potencialmente al corazón.” (It depends on the degree of nerve damage and how quickly we control the vasculitis. With aggressive treatment now, some patients regain partial or full nerve function over time. Without treatment, the damage progresses to more nerves and potentially the heart.)
Eduardo returned to his original question. “Entonces el asma de Alejandra fue la primera fase de esta enfermedad desde el principio.” (So Alejandra’s asthma was the first phase of this disease from the beginning.)
“Sí. El sistema inmune estaba produciendo demasiados eosinófilos y demasiada inflamación impulsada por IL-5 desde hace diez años. El pulmón fue el primer órgano afectado y por eso se manifestó como asma. Pero la misma disregulación inmune que causó el asma es la que ahora está causando la vasculitis. El mepolizumab que ya recibía — que bloquea la IL-5 — estaba tratando la causa desde la raíz. Ahora necesitamos intensificar ese tratamiento y agregar ciclofosfamida para el componente vascuítico activo.” (Yes. The immune system was producing too many eosinophils and too much IL-5-driven inflammation for ten years. The lung was the first organ affected and that is why it manifested as asthma. But the same immune dysregulation that caused the asthma is now causing the vasculitis. The mepolizumab she was already receiving — which blocks IL-5 — was treating the underlying cause. Now we need to intensify that treatment and add cyclophosphamide for the active vasculitic component.)
Alejandra had been quiet through most of the conversation. She asked: “¿Significa que el mepolizumab que ya tomaba me estaba protegiendo el corazón sin que yo lo supiera?” (Does it mean the mepolizumab I was already taking was protecting my heart without me knowing?)
“Probablemente sí,” Rosa said. “El mepolizumab bajó el conteo de eosinófilos de donde estaba antes — sin él, probablemente hubiera llegado antes a esta fase. Ahora que la fase vascuítica está activa, necesitamos más.” (Probably yes. Mepolizumab lowered the eosinophil count from where it was before — without it, you probably would have reached this phase sooner. Now that the vasculitic phase is active, we need more.)